No CrossRef data available.
Article contents
Beyond Monoamines: Glutamatergic Function in Mood Disorders
Published online by Cambridge University Press: 07 November 2014
Abstract
The monoamine theory has implicated abnormalities in serotonin and norepinephrine in the pathophysiology of major depression and bipolar illness and contributed greatly to our understanding of mood disorders and their treatment. Nevertheless, some limitations of this model still exist that require researchers and clinicians to seek further explanation and develop novel interventions that reach beyond the confines of the monoaminergic systems. Recent studies have provided strong evidence that glutamate and other amino acid neurotransmitters are involved in the pathophysiology and treatment of mood disorders. Studies employing in vivo magnetic resonance spectroscopy have revealed altered cortical glutamate levels in depressed subjects. Consistent with a model of excessive glutamate-induced excitation in mood disorders, several antiglutamatergic agents, such as riluzole and lamotrigine, have demonstrated potential antidepressant efficacy. Glial cell abnormalities commonly associated with mood disorders may at least partly account for the impairment in glutamate action since glial cells play a primary role in synaptic glutamate removal. A hypothetical model of altered glutamatergic function in mood disorders is proposed in conjunction with potential antidepressant mechanisms of antiglutamatergic agents. Further studies elucidating the role of the glutamatergic system in the pathophysiology of mood and anxiety disorders and studies exploring the efficacy and mechanism of action of antiglutamatergic agents in these disorders, are likely to provide new targets for the development of novel antidepressant agents.
Information
- Type
- Review Articles
- Information
- Copyright
- Copyright © Cambridge University Press 2005
References
REFERENCES
1.Heninger, GR, Delgado, PL, Charney, DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments inhumans. Pharmacopsychiatry. 1996;29:2–11.CrossRefGoogle Scholar
2.Berman, RM, Narasimhan, M, Charney, DS. Treatment-refractory depression: definitions and characteristics. Depress Anxiety. 1997;5:154–164.3.0.CO;2-D>CrossRefGoogle ScholarPubMed
3.Farvolden, P, Kennedy, SH, Lam, RW. Recent developments in the psychohiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future. Expert Opin Investig Drugs. 2003;12:65–86.CrossRefGoogle ScholarPubMed
4.Coyle, JT, Leski, ML, Morrison, JH. The diverse roles of L-glutamic acid in brain signal transduction. In: Davis, KL, Charney, D, Coyle, JT, Nemeroff, C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Nashville, Tenn: American College of Neuropsychopharmacology/Lippincott Williams & Wilkins; 2002:71–90.Google Scholar
5.Snyder, SH, Ferris, CD. Novel neurotransmitters and their neuropsychiatric relevance. Am J Psychiatry. 2000;157:1738–1751.CrossRefGoogle ScholarPubMed
6.Quiroz, JA, Singh, J, Gould, TD, Denicoff, KD, Zarate, CA, Manji, HK. Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology. Mol Psychiatry. 2004;9:756–776.Google Scholar
7.Hardingham, GE, Bading, H. The Yin and Yang of NMDA receptor signalling. Trends Neurosci. 2003;26:81–89.CrossRefGoogle ScholarPubMed
8.Vanhoutte, P, Bading, H. Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation. Curr Opin Neurobiol. 2003;13:366–371.Google Scholar
9.Shigeri, Y, Seal, RP, Shimamoto, K. Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Rev. 2004;45:250–265.CrossRefGoogle ScholarPubMed
10.Mathews, GC, Diamond, JS. Neuronal glutamate uptake contributes to GABA synthesis and inhibitory synaptic strength. J Neurosci. 2003;23:2040–2048.CrossRefGoogle ScholarPubMed
11.Lebon, V, Petersen, KF, Cline, GW, et al.Astroglial contribution to brain energy metabolism in humans revealed by 13C nuclear magnetic resonance spectroscopy: elucidation of the dominant pathway for neurotransmitter glutamate repletion and measurement of astrocytic oxidative metabolism. J Neurosci. 2002;22:1523–1531.CrossRefGoogle ScholarPubMed
12.Xi, ZX, Shen, H, Baker, DA, Kalivas, PW. Inhibition of non-vesicular glutamate release by group III metabotropic glutamate receptors in the nucleus accumbens. J Neurochem. 2003;87:1204–1212.Google Scholar
13.Coyle, JT, Schwarcz, R. Mind glue: implications of glial cell biology for psychiatry. Arch Gen Psychiatry. 2000;57:90–93.CrossRefGoogle ScholarPubMed
14.Haydon, PG. GLIA: listening and talking to the synapse. Nat Rev Neurosci. 2001;2:185–193.CrossRefGoogle Scholar
15.Ullian, EM, Sapperstein, SK, Christopherson, KS, Barres, BA. Control of synapse number by glia. Science. 2001;291:657–661.Google Scholar
16.Bliss, TVP, Collingridge, GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31–38.Google Scholar
17.Lipton, SA, Rosenberg, PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330:613–621.Google ScholarPubMed
18.Kaul, M, Garden, GA, Lipton, SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature. 2001;410:988–994.CrossRefGoogle ScholarPubMed
19.Lancelot, E, Beal, MF. Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res. 1998;116:331–347.Google Scholar
20.Tariot, PN, Farlow, MR, Grossberg, GT, et al.Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317–324.CrossRefGoogle ScholarPubMed
21.Kim, JS, Schmid-Burgk, W, Claus, D, Kornhuber, HH. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr. 1982;232:299–304.Google Scholar
22.Altamura, CA, Mauri, MC, Ferrara, A, Moro, AR, D'Andrea, G, Zamberlan, F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry. 1993;150:1731–1733.Google ScholarPubMed
23.Mauri, MC, Ferrara, A, Boscati, L, et al.Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology. 1998;37:124–129.CrossRefGoogle ScholarPubMed
24.Maes, M, Verkerk, R, Vandoolaeghe, E, Lin, A, Scharpe, S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand. 1998;97:302–308.Google Scholar
25.Francis, PT, Poynton, A, Lowe, SL, et al.Brain amino acid concentrations and Ca2+-dependent release in intractable depression assessed antemortem. Brain Res. 1989;494:315–324.CrossRefGoogle ScholarPubMed
26.Nowak, G, Ordway, GA, Paul, IA. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. 1995;675:157–164.CrossRefGoogle ScholarPubMed
27.Nudmamud-Thanoi, S, Reynolds, GP. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci Lett. 2004;372:173–177.CrossRefGoogle ScholarPubMed
28.Karolewicz, B, Stockmeier, C, Ordway, GA. Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression. Neuropsychopharmacology. 2005 05 25; [Epub ahead of print]Google Scholar
29.Karolewicz, B, Szebeni, K, Stockmeier, CA, et al.Low nNOS protein in the locus coeruleus in major depression. J Neurochem. 2004;91:1057–1066.Google Scholar
30.Auer, DP, Putz, B, Kraft, E, Lipinski, B, Schill, J, Holsboer, F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 2000;47:305–313.CrossRefGoogle Scholar
31.Mirza, Y, Tang, J, Russell, A, et al.Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression. J Am Acad of Child Adolesc Psychiatry. 2004;43:341–348.CrossRefGoogle ScholarPubMed
32.Rosenberg, DR, Mirza, Y, Russell, A, et al.Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad of Child Adolesc Psychiatry. 2004;43:1146–1153.Google Scholar
33.Dager, SR, Friedman, SD, Parow, A, et al.Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry. 2004;61:450–458.Google Scholar
34.Sanacora, G, Gueorguieva, R, Epperson, CN, et al.Subtype-specific alterations of γ-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004;61:705–713.CrossRefGoogle ScholarPubMed
35.Scarr, E, Pavey, G, Sundram, S, MacKinnon, A, Dean, B. Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disord. 2003;5:257–264.Google Scholar
36.Mundo, E, Tharmalingham, S, Neves-Pereira, M, et al.Evidence that the N-methyl-D-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder. Mol Psychiatry. 2003;8:241–245.CrossRefGoogle ScholarPubMed
37.Michael, N, Erfurth, A, Ohrmann, P, Arolt, V, Heindel, W, Pfleiderer, B. Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression. Neuropsychopharmacology. 2003;28:720–725.CrossRefGoogle ScholarPubMed
38.Binesh, N, Kumar, A, Hwang, S, Mintz, J, Thomas, MA. Neurochemistry of late-life major depression: a pilot two dimensional MR spectroscopic study. J Magn Reson. 2004;20:1039–1045.Google ScholarPubMed
39.Castillo, M, Kwock, L, Courvoisie, H, Hooper, SR. Proton MR spectroscopy in children with bipolar affective disorder: preliminary observations. AJNR Am J Neuroradiol. 2000;21:832–838.Google ScholarPubMed
40.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.CrossRefGoogle ScholarPubMed
41.Sanacora, G, Gueorguieva, R, Epperson, CN, et al.Subtype-specific alterations of GABA and glutamate in major depression. Arch Gen Psychiatry. 2004;61:705–713.CrossRefGoogle ScholarPubMed
42.First, M, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for DSM-IV Axis I Disorders—Patient Edition (SCID-I/P, version 2.0). New York, NY: Biometrie Research Department, New York State Psychiatric Institute; 1995.Google Scholar
43.Ongur, D, Drevets, WC, Price, JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA. 1998;95:13290–13295.CrossRefGoogle ScholarPubMed
44.Rajkowska, G, Miguel-Hidalgo, JJ, Wei, J, et al.Morphometric evidence of neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999;45:1085–1098.CrossRefGoogle ScholarPubMed
45.Rajkowska, G, Halaris, A, Selemon, LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder, [see comment]. Biol Psychiatry. 2001;49:741–752.CrossRefGoogle Scholar
46.Cotter, D, Mackay, D, Landau, S, Kerwin, R, Everall, I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry. 2001;58:545–553.CrossRefGoogle ScholarPubMed
47.Cotter, D, Pariante, CM, Rajkowska, G. Glial pathology and major psychiatric disorders. In: Agam, G, Everall, I, Belmaker, RH, eds. The Postmortem Brain in Psychiatric Research. Boston, Mass: Kluwer Academic Publishers; 2002:49–73.Google Scholar
48.Bowley, MP, Drevets, WC, Ongur, D, Price, JL. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry. 2002;52:404–412.CrossRefGoogle ScholarPubMed
49.Miguel-Hidalgo, JJ, Baucom, C, Dilley, G, et al.Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry. 2000;48:861–873.Google Scholar
50.Skolnick, P. Antidepressants for the new millennium. Eur J Pharmacol. 1999;375:31–40.CrossRefGoogle ScholarPubMed
51.Skolnick, P, Legutko, B, Li, X, Bymaster, FP. Current perspectives on the development of non-hiogenic amine-based antidepressants. Pharmacol Res. 2001;43:411–423.CrossRefGoogle ScholarPubMed
52.Hood, WF, Compton, RP, Monahan, JB. D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett. 1989;98:91–95.Google Scholar
53.Crane, G. Cycloserine as an antidepressant agent. Am J Psychiatry. 1959;115:1025–1026.Google Scholar
54.Crane, G. The psychotropic effect of cycloserine: a new use of an antibiotic. Compr Psychiatry. 1961;2:51–59.Google Scholar
55.Parkes, JD, Calver, DM, Zilkha, KJ, Knill-Jones, RP. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet. 1970;1:259–262.Google Scholar
56.Mindham, RH, Marsden, CD, Parkes, JD. Psychiatric symptoms during 1-dopa therapy for Parkinson's disease and their relationship to physical disability. Psychol Med. 1976;6:23–33.Google Scholar
57.Vale, S, Espejel, MA, Dominguez, JC. Amantadine in depression. Lancet. 1971;2:437.CrossRefGoogle ScholarPubMed
58.Dietrich, DE, Kleinschmidt, A, Hauser, U, et al.Word recognition memory before and after successful treatment of depression. Pharmacopsychiatry. 2000;33:221–228.Google Scholar
59.Ferszt, R, Kuhl, KP, Bode, L, et al.Amantadine revisited: an open trial of amantadinesulfate treatment in chronically depressed patients with Borna disease virus infection. Pharmacopsychiatry. 1999;32:142–147.Google Scholar
60.Huber, TJ, Dietrich, DE, Emrich, HM. Possible use of amantadine in depression. Pharmacopsychiatry. 1999;32:47–55.Google Scholar
61.Stryjer, R, Strous, RD, Shaked, G, et al.Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol. 2003;18:93–96.CrossRefGoogle ScholarPubMed
62.Gortelmeyer, R, Erbler, H, Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelforschung. 1992;42:904–913.Google ScholarPubMed
63.Ambrozi, L, Danielczyk, W. Treatment of impaired cerebral function in psychogeriatric patients with memantine–results of a phase II double-blind study. Pharmacopsychiatry. 1988;21:144–146.Google Scholar
64.Zarate, CA Jr, Singh, J, Quiroz, JA, et al.Memantine in major depression: a double-blind placebo-controlled study. Am J Psychiatry. In press.Google Scholar
65.Peeters, M, Romieu, R, Maurice, T, Su, TP, Maloteaux, JM, Hermans, E. Involvement of the sigmal receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci. 2004;19:2212–2220.Google Scholar
66.Kornhuber, J, Schoppmeyer, K, Riederer, P. Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex. Neurosci Lett. 1993;163:129–131.Google Scholar
67.Zarate, CA Jr, Quiroz, J, Gray, NA, et al.Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders. Role of the glutamatergic system. Ann N Y Acad Sei 2003;1003:273–291.CrossRefGoogle ScholarPubMed
68.Berman, RM, Cappiello, A, Anand, A, et al.Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–354.Google Scholar
69.Kudoh, A, Takahira, Y, Katagai, H, Takazawa, T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg. 2002;95:114–118.Google Scholar
70.Ostroff, R, Gonzales, M, Sanacora, G. Antidepressant effect of ketamine during ECT. Am J Psychiatry. 2005;162:1385–1386.CrossRefGoogle ScholarPubMed
71.Bowden, CL, Karren, NU. Lamotrigine in the treatment of bipolar disorder. Expert Opin Pharmacother. 2002;3:1513–1519.CrossRefGoogle ScholarPubMed
72.Hurley, SC. Lamotrigine update and its use in mood disorders. Ann Pharmacotherapy. 2002;36:860–873.Google Scholar
73.Bowden, CL. Novel treatments for bipolar disorder.[erratum appears in Expert Opin Investig Drugs 2001 Jul;10(7):following 1205]. Expert Opin Investig Drugs. 2001;10:661–671.Google Scholar
74.Frye, MA, Ketter, TA, Kimbrell, TA, et al.A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20:607–614.Google Scholar
75.Calabrese, JR, Suppes, T, Bowden, CL, et al.A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000;61:841–850.Google Scholar
76.Bowden, CL, Calabrese, JR, Sachs, G, et al.A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60:392–400.CrossRefGoogle ScholarPubMed
77.Barbee, JG, Jamhour, NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry. 2002;63:737–741.Google Scholar
78.Maltese, TM. Adjunct lamotrigine treatment for major depression. Am J Psychiatry. 1999;156:1833.Google Scholar
79.Rocha, FL, Hara, C. Lamotrigine augmentation in unipolar depression. Int Clin Psychopharmacol. 2003;18:97–99.Google Scholar
80.Obrocea, GV, Dunn, RM, Frye, MA, et al.Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry. 2002;51:253–260.Google Scholar
81.Normann, C, Hummel, B, Scharer, LO, Horn, M, Grunze, H, Walden, J. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry. 2002;63:337–344.CrossRefGoogle ScholarPubMed
82.Barbosa, L, Berk, M, Vorster, M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients with concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003;64:403–407.Google Scholar
83.Frizzo, ME, Dall'Onder, LP, Dalcin, KB, Souza, DO. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol. 2004;24:123–128.CrossRefGoogle ScholarPubMed
84.Zarate, CA Jr, Payne, JL, Quiroz, J, et al.An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004;161:171–174.Google Scholar
85.Coric, V, Milanovic, S, Wasylink, S, Patel, P, Malison, R, Krystal, JH. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmocoiogy (Berl). 2003;167:219–220.Google Scholar
86.Sanacora, G, Kendell, SF, Fenton, L, Coric, V, Krystal, JH. Riluzole augmentation for treatment-resistant depression. Am J Psychiatry. 2004;161.Google Scholar
87.Zarate, CA Jr, Quiroz, JA, Singh, JB, et al.An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57:430–432.Google Scholar
88.Pilc, A, Klodzinska, A, Branski, P, et al.Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology. 2002;43:181–187.Google Scholar
89.Wieronska, JM, Szewczyk, B, Branski, P, Palucha, A, Pilc, A. Antidepressant-like effect of MPEP, a potent, selective and systematically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids. 2002;23:213–216.Google Scholar
90.Tatarczynska, E, Klodzinska, A, Chojnacka-Wojcik, E, et al.Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol. 2001;132:1423–1430.Google Scholar
91.Chaki, S, Yoshikawa, T, Hirota, S, et al.MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology. 2004;46:457–467.Google Scholar
92.Trullas, R, Skolnick, P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990;185:1–10.CrossRefGoogle ScholarPubMed
93.Panconi, E, Roux, J, Attenbaumer, M, Hampe, S, Porsolt, RD. MK-801 and enantiomers: potential antidepressants or false positives in classical screening models? Pharmacol Biochem Behav. 1993;46:15–20.Google Scholar
94.Maj, J, Rogoz, Z, Skuza, G, Sowinska, H. Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. Eur Neuropsychopharmacol. 1992;2:37–41.CrossRefGoogle ScholarPubMed
95.Meloni, D, Gambarana, C, De Montis, MG, Dal Pra, P, Taddei, I, Tagliamonte, A. Dizocilpine antagnonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacol Biochem Behav. 1993;46:423–426.Google Scholar
96.Papp, M, Moryl, E. New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors. Pol J Pharmocol. 1993;45:549–553.Google Scholar
97.Ossowska, G, Klenk-Majewska, B, Szymczyk, G. The effect of NMDA antagonists on footshock-induced fighting behavior in chronically stressed rats. J Physiol Pharmacol. 1997;48:127–135.Google Scholar
98.Yilmaz, A, Schulz, D, Aksoy, A, Canbeyli, R. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav. 2002;71:341–344.Google Scholar
99.Kroczka, B, Branski, P, Palucha, A, Pilc, A, Nowak, G. Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull. 2001;55:297–300.Google Scholar
100.Kroczka, B, Zieba, A, Dudek, D, Pilc, A, Nowak, G. Zinc exhibits an antidepressant-like effect in the forced swimming test in mice. Pol J Pharmacol. 2000;52:403–406.Google Scholar
101.Szewczyk, B, Branski, P, Wieronska, JM, Palucha, A, Pilc, A, Nowak, G. Interaction of zinc with antidepressants in the forced swimming test in mice. Pol J Pharmacol. 2002;54:681–685.Google Scholar
102.Rosa, AO, Lin, J, Calixto, JB, Santos, AR, Rodrigues, AL. Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav Brain Res. 2003;144:87–93.Google Scholar
103.Wyska, E, Szymura-Oleksiak, J, Opoka, Wet al.Pharmacokinetic interaction after joint administration of zinc and imipramine in forced swim test in mice. Pol J Pharmacol. 2004;56:479–484.Google Scholar
104.Nowak, G, Szewczyk, B, Wieronska, JM, et al.Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull. 2003;61:159–164.Google Scholar
105.Przegalinski, E, Tatarczynska, E, Deren-Wesolek, A, Chojnacka-Wojcik, E. Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology. 1997;36:31–37.CrossRefGoogle Scholar
106.Maj, J, Rogoz, Z, Skuza, G, Sowinska, H. The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in the forced swimming test. Pol J Pharmacol Pharm 1992;44:337–346.Google ScholarPubMed
107.Papp, M, Moryl, E. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol. 1994;263:1–7.CrossRefGoogle Scholar
108.Trullas, R, Folio, T, Young, A, Miller, R, Boje, K, Skolnick, P. 1-aminocyclopropanecarhoxylates exhibit antidepressant and anxiolytic actions in animal models. Eur J Pharmacol. 1991;203:379–385.Google Scholar
109.Sanacora, G, Rothman, DL, Mason, GF, Krystal, JH. Clinical studies implementing glutamate neurotransmission in mood disorders. In: Moghaddam, B, Wolf, ME, eds. Glutamate and Diorders of Cognition and Motivation, vol. 1003.2003:292–308.Google Scholar
110.Sanacora, G, Mason, GF, Krystal, JH. Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Crit Rev Neurobiol. 2000;14:23–45.Google Scholar
111.Krystal, JH, Sanacora, G, Blumberg, H, et al.Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry. 2002;7:S71–S80.CrossRefGoogle ScholarPubMed
112.Kendell, SF, Krystal, JH, Sanacora, G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets. 2005;9:153–168.Google Scholar
113.Petty, F, Kramer, GL, Hendrickse, W. GABA and depression. In: Mann, JJ, Kupler, DJ, eds. Biology of Depressive Disorders, Part A: A Systems Perspective. New York, NY: Plenum Press; 1993:79–108.Google Scholar
114.Sanacora, G, Mason, GF, Rothman, DL, et al.Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1999;56:1043–1047.Google Scholar
115.Sanacora, G, Mason, GF, Rothman, DL, Ciarcia, JJ, Ostroff, RB, Krystal, JH. Increased occipital cortex GABA concentrations following electroconvulsive therapy in depressed patients. Am J Psychiatry. 2003;160:577–579.Google Scholar
116.Sanacora, G, Mason, GF, Rothman, DL, Krystal, JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry. 2002;159:663–665.Google Scholar
117.Bhagwagar, Z, Wylezinska, M, Taylor, M, Jezzard, P, Watthews, PM, Cowen, PJ. Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. Am J Psychiatry. 2004;161:368–370.CrossRefGoogle ScholarPubMed
118.Mason, GF, Sanacora, G, Hundal, R, et al.Preliminary evidence of reduced cortical GABA synthesis rate in major depression. Soc Neurosci. 2001;Abstr 142.6.Google Scholar
119.Heckers, S, Stone, D, Walsh, J, Shick, J, Koul, P, Benes, FM. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry. 2002;59:521–529.Google Scholar
120.Woo, T-UW, Walsh, JP, Benes, FM. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry. 2004;61:649–657.Google Scholar
121.Fatemi, SH, Stary, JM, Earle, JA, Araghi-Niknam, M, Eagan, E. GAGAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and reelin proteins in cerebellum. Schizophr Res. 2005;72:109–122.Google Scholar
122.Padmos, RC, Bekris, L, Knijff, EM, et al.A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. Biol Psychiatry. 2004;56:476–482.Google Scholar
123.Petty, F, Trivedi, MH, Fulton, M, Rush, AJ. Benzodiazepines as antidepressants: does GABA play a role in depression? Biol Psychiatry. 1995;38:578–591.Google Scholar
124.Schatzberg, AF, Cole, JO. Benzodiazepines in depressive disorders. Arch Gen Psychiatry. 1978;35:1359–1365.Google Scholar
125.Tiller, JW, Schweitzer, I, Maguire, KP, Davis, B. Is diazepam an antidepressant? Br J Psychiatry. 1989;155:483–459.Google Scholar
126.Furukawa, T, Streiner, D, Young, L. Antidepressant and benzodiazepine for major depression. Cochrane Review. Chichester, UK: The Cochrane Library: John Wiley & Sons, Ltd.; 2004.Google Scholar
127.Rosenthal, M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry. 2003;64:1245–1249.Google Scholar
128.Carpenter, L, Tyrka, A, Schecter, J, Haggarty, R, Price, L. Tiagabine for major depression with anxiety. Biol Psychiatry. 2003;53:38S.Google Scholar
129.Suppes, T, Chisholm, KA, Dhavale, D, et al.Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord. 2002;4:283–289.Google Scholar
130.Suppes, T. Review of the use of topiramate for treatment of bipolar disorders. J Clin Psychopharmacol. 2002;22:599–609.Google Scholar
131.Davis, LL, Kabel, D, Patel, D, et al.Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull. 1996;32:647–652.Google Scholar
132.Yang, CH, Huang, CC, Hsu, KS. Behavioral stress enhances hippocampal CA1 long-term depression throught the blockade of the glutamate uptake. J Neurosci. 2005;25:4288–4293.CrossRefGoogle Scholar
133.Nakagawa, S, Kim, JE, Lee, R, et al.Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J Neurosci. 2002;22:3673–3682.CrossRefGoogle ScholarPubMed
134.Duman, RS, Malberg, J, Nakagawa, S. Regulation of adult neurogenesis by psychotropic drugs and stress. J Pharmcol Expe Ther. 2001;299:401–407.Google Scholar
135.Kodama, M, Fujioka, T, Duman, RS. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004;56:570–580.Google Scholar
136.Fuchs, E, Czeh, B, Kole, MH, Michaelis, T, Lucassen, PJ. Alterations of neuroplasticity in depression: the hippocampus and beyond. Eur Neuropsychopharmacol. 2004;14(suppl 5):S481–S490.Google Scholar
137.Rothstein, JD, Jin, L, Dykes-Hoberg, M, Kuncl, RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci U S A. 1993;90:6591–6595.Google Scholar
138.Si, X, Miguel-Hidalgo, JJ, O'Dwver, G, Stockmeier, CA, Rajkowska, G. Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology. 2004;29:2088–2096.Google Scholar
139.Sem'yanov, AV. Diffusional extrasynaptic neurotransmission via glutamate and GABA. Neurosci Behav Physiol. 2005;35:253–266.Google Scholar
140.Moghaddam, B, Adams, BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998;281:1349–1352.Google Scholar
141.Krystal, JH, Abi-Saab, W, Perry, E, et al.Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the the group II metabotropic glutamate receptor (mGluR) agonist, LY354740, in healthy human subjects. Psychopharmocoiogy (Beel). 2005;179:303–309.Google Scholar
142.Anand, A, Charney, DS, Oren, DA, et al.Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57:270–276.Google Scholar
143.Li, X, Tizzano, JP, Griffey, K, Clay, M, Lindstrom, T, Skolnick, P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology. 2001;40:1028–1033.Google Scholar
144.Quirk, JC, Nisenbaum, ES. LY404187: a novel positive allosteric modulator of AMPA receptors. CNS Drug Rev. 2002;8:255–282.Google Scholar
145.Duman, RS, Heninger, GR, Nestler, EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597–606.Google Scholar
146.Nacher, J, Rosell, DR, Alonso-Llosa, G, McEwen, BS. NMDA receptor antagonist treatment induces a long-lasting increase in the number of proliferating cells, PSA-NCAM-immunoreactive granule neurons and radial glia in the adult rat dentate gyrus. Eur J Neurosci. 2001;13:512–520.CrossRefGoogle ScholarPubMed
147.Nacher, J, Alonso-Llosa, G, Rosell, DR, McEwen, BS. NMDA receptor antagonist treatment increases the production of new neurons in the aged rat hippocampus. Neurobiol Aging. 2003;24:273–284.Google Scholar
148.Mackowiak, M, O'Neill, MJ, Hicks, CA, Bleakman, D, Skolnick, P. An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study. Neuropharmacology. 2002;43:1–10.Google Scholar
149.Legutko, B, Li, X, Skolnick, P. Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology. 2001;40:1019–1027.Google Scholar
150.Moghaddam, B, Adams, B, Verma, A, Daly, D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921–2927.Google Scholar
- 238
- Cited by